SurfingNASH reviews a riveting NASH-TAG 2023 in a two-part wrap-up episode featuring Amy Articolo, Naim Alkhouri and Donna Cryer. The panelists discuss a myriad of topics spanning across the therapeutic efficacy of resmetirom, NITs, bariatric surgery and the trajectory of regulatory science.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the final installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Naim Alkhouri, Stephen Harrison and Ian Rowe to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This final conversation discusses the diversity of populations with NASH before closing with the group’s predictions into a new year in the field of Fatty Liver disease.
Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
This episode is Sponsored by Resoundant.
How can epidemiology-driven data modeling improve our setting strategies and targets for diagnostic and drug development?
This Episode is Sponsored by Madrigal Pharmaceuticals: Once we acknowledge the potential for economic, social and medical damage that the increasing trend toward adolescent and pediatric NAFLD will cause, what solutions do we have? Can Liver Health education be effective?
This Episode is Sponsored by Madrigal Pharmaceuticals: What Can We Learn About Health Disparities In NASH Epidemiology and Treatment From the Content of NASH Connect?
This Episode Is Sponsored By Madrigal Pharmaceuticals. What Insights About NASH and NAFLD Emerged From the Chronic Liver Disease Foundation’s 2nd Annual Liver Connect and NASH Connect?
Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.
